Praluent Dosage/Direction for Use

Posology: Prior to initiating Praluent secondary causes of hyperlipidaemia or mixed dyslipidaemia (e.g., nephrotic syndrome, hypothyroidism) should be excluded.
The usual starting dose for Praluent is 75 mg administered subcutaneously once every 2 weeks. Patients requiring larger LDL-C reduction (>60%) may be started on 150 mg once every 2 weeks, or 300 mg once every 4 weeks (monthly), administered subcutaneously.
The dose of Praluent can be individualised based on patient characteristics such as baseline LDL-C level, goal of therapy, and response. Lipid levels can be assessed 4 to 8 weeks after treatment initiation or titration, and dose adjusted accordingly (up-titration or down-titration). If additional LDL-C reduction is needed in patients treated with 75 mg once every 2 weeks or 300 mg once every 4 weeks (monthly), the dosage may be adjusted to the maximum dosage of 150 mg once every 2 weeks.
If a dose is missed, the patient should administer the injection as soon as possible and thereafter resume treatment on the original schedule.
Special populations: Paediatric population: The safety and efficacy of Praluent in children and adolescents less than 18 years of age have not been established. No data are available.
Elderly: No dose adjustment is needed for elderly patients.
Hepatic impairment: No dose adjustment is needed for patients with mild or moderate hepatic impairment. No data are available in patients with severe hepatic impairment.
Renal impairment: No dose adjustment is needed for patients with mild or moderate renal impairment. Limited data are available in patients with severe renal impairment (see Pharmacology: Pharmacokinetics under Actions).
Body weight: No dose adjustment is needed in patients based on weight.
Method of administration: Subcutaneous use.
Praluent is injected as a subcutaneous injection into the thigh, abdomen or upper arm.
To administer the 300 mg dose, give two 150 mg injections consecutively at two different injection sites. It is recommended to rotate the injection site with each injection.
Praluent should not be injected into areas of active skin disease or injury such as sunburns, skin rashes, inflammation, or skin infections.
Praluent must not be co-administered with other injectable medicinal products at the same injection site.
The patient may either self-inject Praluent, or a caregiver may administer Praluent, after guidance has been provided by a healthcare professional on proper subcutaneous injection technique.
Precautions to be taken before handling: Praluent should be allowed to warm to room temperature prior to use. Praluent should be used as soon as possible after it has warmed up (see Storage).
Each pre-filled pen is for single use only.